Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012

There is no fulltext present in this item.

Title:	Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012
Author(s):	Dinmohamed, A.G.; Visser, O; Norden, Y. Van; Blijlevens, N.M.A. ; Cornelissen, J.J.; Huls, G.A.; Huijgens, P.C.; Sonneveld, P.; Loosdrecht, A.A. van de; Ossenkoppele, G.J.; Lowenberg, B.; Jongen-Lavrencic, M.
Publication year:	2016
Source:	Leukemia, vol. 30, iss. 1, (2016), pp. 24-31
ISSN:	0887-6924
DOI:	https://doi.org/10.1038/leu.2015.188
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/171855
Display more details
Subject:	Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences
Organization:	Haematology
Journal title:	Leukemia
Volume:	vol. 30
Issue:	iss. 1
Page start:	p. 24
Page end:	p. 31
Abstract:	Large, comprehensive population-based studies in acute myeloid leukemia (AML) are scarce. We conducted a nationwide population-based study on treatment, trial participation and survival among all adult patients diagnosed with AML (N=12,032) and acute promyelocytic leukemia (APL; N=585) in the Netherlands between 1989-2012. Patients were categorized into four periods and four age groups (18-40, 41-60, 61-70, and >70 years). The application of allogeneic stem cell transplantation increased over time among AML patients up to age 70. For APL patients, the use of chemotherapy increased across all age groups. When a clinical trial was open for accrual in the Netherlands, the inclusion rates were 68, 57, 30 and 12% for AML patients in the four age groups, respectively (data for APL unavailable). Relative survival improved over time among AML (up to age 70) and APL patients. In the period 2007-2012, 5-year relative survival rates were 54, 38, 14 and 2% for AML patients and 84, 75, 54 and 37% for APL patients in the four age groups, respectively. As survival remained poor for older AML patients over the last two decades, clinical trials, and active participation in those trials, are warranted that explore innovative treatment strategies for this elderly population.Leukemia accepted article preview online, 17 July 2015. doi:10.1038/leu.2015.188.